These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 6474162

  • 1. Neuroleptic-induced decrease in plasma homovanillic acid and antipsychotic activity in schizophrenic patients.
    Pickar D, Labarca R, Linnoila M, Roy A, Hommer D, Everett D, Paul SM.
    Science; 1984 Aug 31; 225(4665):954-7. PubMed ID: 6474162
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Changes in plasma homovanillic acid concentrations in schizophrenic patients following neuroleptic discontinuation.
    Davidson M, Kahn RS, Powchik P, Warne P, Losonczy MF, Kaminsky R, Apter S, Jaff S, Davis KL.
    Arch Gen Psychiatry; 1991 Jan 31; 48(1):73-6. PubMed ID: 1670618
    [Abstract] [Full Text] [Related]

  • 4. Circadian variation of plasma homovanillic acid levels is attenuated by fluphenazine in patients with schizophrenia.
    Doran AR, Labarca R, Wolkowitz OM, Roy A, Douillet P, Pickar D.
    Arch Gen Psychiatry; 1990 Jun 31; 47(6):558-63. PubMed ID: 2350208
    [Abstract] [Full Text] [Related]

  • 5. Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations.
    Davidson M, Kahn RS, Knott P, Kaminsky R, Cooper M, DuMont K, Apter S, Davis KL.
    Arch Gen Psychiatry; 1991 Oct 31; 48(10):910-3. PubMed ID: 1929760
    [Abstract] [Full Text] [Related]

  • 6. Plasma homovanillic acid levels and therapeutic outcome in schizophrenics: comparisons of neuroleptic-naive first-episode patients and patients with disease exacerbation due to neuroleptic discontinuance.
    Akiyama K, Tsuchida K, Kanzaki A, Ujike H, Hamamura T, Kondo K, Mutoh S, Miyanagi K, Kuroda S, Otsuki S.
    Biol Psychiatry; 1995 Nov 15; 38(10):639-48. PubMed ID: 8555375
    [Abstract] [Full Text] [Related]

  • 7. Persistence of cyclicity of the plasma dopamine metabolite, homovanillic acid, in neuroleptic treated schizophrenic patients.
    Davila R, Zumarraga M, Andia I, Friedhoff AJ.
    Life Sci; 1989 Nov 15; 44(16):1117-21. PubMed ID: 2565009
    [Abstract] [Full Text] [Related]

  • 8. The acute effects of central- and peripheral-acting dopamine antagonists on plasma HVA in schizophrenic patients.
    Konicki PE, Owen RR, Litman RE, Pickar D.
    Life Sci; 1991 Nov 15; 48(14):1411-6. PubMed ID: 2008157
    [Abstract] [Full Text] [Related]

  • 9. Neuroleptics, dopamine, and schizophrenia.
    Pickar D.
    Psychiatr Clin North Am; 1986 Mar 15; 9(1):35-48. PubMed ID: 2870480
    [Abstract] [Full Text] [Related]

  • 10. Increments in plasma homovanillic acid concentrations after neuroleptic discontinuation are associated with worsening of schizophrenic symptoms.
    Khan RS, Amin F, Powchik P, Knott P, Goldstein M, Apter S, Kerman B, Jaff S, Davidson M.
    Prog Neuropsychopharmacol Biol Psychiatry; 1990 Mar 15; 14(6):879-84. PubMed ID: 1980541
    [Abstract] [Full Text] [Related]

  • 11. Plasma homovanillic acid in schizophrenics: supportive evidence for the two-subtype hypothesis.
    Chen TY, Lee CF, Lung FW, Lee TC, Lin WL, Hu WH, Yeh EK, Chang WH.
    Taiwan Yi Xue Hui Za Zhi; 1989 Jun 15; 88(6):584-8. PubMed ID: 2571672
    [Abstract] [Full Text] [Related]

  • 12. Longitudinal changes in symptoms and plasma homovanillic acid levels in chronically medicated schizophrenic patients.
    Suzuki E, Kanba S, Nibuya M, Adachi S, Sekiya U, Shintani F, Kinoshita N, Yagi G, Asai M.
    Biol Psychiatry; 1994 Nov 15; 36(10):654-61. PubMed ID: 7880934
    [Abstract] [Full Text] [Related]

  • 13. Dopamine and schizophrenia.
    Crow TJ, Johnstone EC, Deakin JF, Longden A.
    Lancet; 1976 Sep 11; 2(7985):563-6. PubMed ID: 60635
    [Abstract] [Full Text] [Related]

  • 14. Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients. Preliminary results.
    Wolkowitz OM, Breier A, Doran A, Kelsoe J, Lucas P, Paul SM, Pickar D.
    Arch Gen Psychiatry; 1988 Jul 11; 45(7):664-71. PubMed ID: 3289524
    [Abstract] [Full Text] [Related]

  • 15. A central 6-hydroxydopamine lesion prevents fluphenazine-induced increase in plasma homovanillic acid.
    Labarca R, Thomas JW, Koulu M, Kim YS, Janowsky A, Wilkinson L, Linnoila M, Paul SM, Pickar D.
    Brain Res Bull; 1988 May 11; 20(5):567-71. PubMed ID: 3133084
    [Abstract] [Full Text] [Related]

  • 16. Plasma homovanillic acid as a predictor of response to neuroleptics.
    Davila R, Manero E, Zumarraga M, Andia I, Schweitzer JW, Friedhoff AJ.
    Arch Gen Psychiatry; 1988 Jun 11; 45(6):564-7. PubMed ID: 3377643
    [Abstract] [Full Text] [Related]

  • 17. Perspectives on a time-dependent model of neuroleptic action.
    Pickar D.
    Schizophr Bull; 1988 Jun 11; 14(2):255-68. PubMed ID: 2904694
    [Abstract] [Full Text] [Related]

  • 18. Plasma homovanillic acid and tardive dyskinesia during neuroleptic maintenance and withdrawal.
    Kirch D, Hattox S, Bell J, Murphy R, Freedman R.
    Psychiatry Res; 1983 Jul 11; 9(3):217-23. PubMed ID: 6137850
    [Abstract] [Full Text] [Related]

  • 19. Biochemical alterations produced by neuroleptics in man: studies of plasma homovanillic acid in schizophrenic patients.
    Pickar D, Wolkowitz OM, Labarca R, Doran AR, Breier A, Paul SM.
    Psychopharmacol Ser; 1987 Jul 11; 3():248-54. PubMed ID: 3823092
    [No Abstract] [Full Text] [Related]

  • 20. Low-dose apomorphine reduces serum homovanillic acid concentrations in schizophrenic patients.
    Cutler NR, Jeste DV, Karoum F, Wyatt RJ.
    Life Sci; 1982 Mar 01; 30(9):753-6. PubMed ID: 7070229
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.